Four key factors can greatly impact how much weight people lose while taking GLP-1 drugs like Ozempic, Wegovy, Victoza, and Saxenda. Here's what to know.

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the average weight loss seen with semaglutide.

Ozempic and Wegovy (semaglutide) promoted the loss of 10% or more body weight in 61% of people being treated for obesity and 23% being treated for diabetes after a year on the drugs, researchers reported Sept. 13 in the journal JAMA Network Open.

Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic -- so what was that journey like for the scientists involved?

Research has shown there are plenty of perks of using a medication like Ozempic for weight loss. But, given that this is a drug, there are some potential downsides to consider, too. New research published in JAMA Network Open links GLP-1 receptor agonists—a class of medications that includes semaglutide medications like Ozempic and Wegovy—to a loss of bone density.